Author

Guillaume Bouguen

SWITCH FROM INTRAVENOUS TO SUB-CUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: WHICH CONSEQUENCES FROM A PHARMACOKINETIC PERSPECTIVE?
SWITCH FROM INTRAVENOUS TO SUB-CUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: WHICH CONSEQUENCES FROM A PHARMACOKINETIC PERSPECTIVE?

REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN USTEKINUMAB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT
REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN USTEKINUMAB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT

Guillaume Bouguen  et al.

DEVELOPMENT AND VALIDATION OF A DEDICATED SCORE TO ASSESS TRANSMURAL RESPONSE AND TRANSMURAL HEALING IN PATIENTS WITH CROHN’S DISEASE
DEVELOPMENT AND VALIDATION OF A DEDICATED SCORE TO ASSESS TRANSMURAL RESPONSE AND TRANSMURAL HEALING IN PATIENTS WITH CROHN’S DISEASE

Guillaume Bouguen  et al.

REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN TOFACITINIB AND USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT: LONG-TERM RESULTS FROM THE TORUS STUDY
REAL-WORLD COMPARISON OF EFFECTIVENESS BETWEEN TOFACITINIB AND USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS EXPOSED TO AT LEAST ONE ANTI-TNF AGENT: LONG-TERM RESULTS FROM THE TORUS STUDY

Guillaume Bouguen  et al.

SWITCH FROM INTRAVENOUS TO SUB-CUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: WHICH CONSEQUENCES FROM A PHARMACOKINETIC PERSPECTIVE?
SWITCH FROM INTRAVENOUS TO SUB-CUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: WHICH CONSEQUENCES FROM A PHARMACOKINETIC PERSPECTIVE?

Guillaume Bouguen  et al.

DEEP ENDOSCOPIC ULCERATIONS ARE NOT ASSOCIATED WITH THE NEED FOR SURGERY OR COMPLICATED BEHAVIOR: A POPULATION-BASED STUDY
DEEP ENDOSCOPIC ULCERATIONS ARE NOT ASSOCIATED WITH THE NEED FOR SURGERY OR COMPLICATED BEHAVIOR: A POPULATION-BASED STUDY

Guillaume Bouguen  et al.

MESENCHYMAL STEM CELLS INJECTION INTO COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE: PRELIMINARY REAL-LIFE RESULTS
MESENCHYMAL STEM CELLS INJECTION INTO COMPLEX PERIANAL FISTULAS IN CROHN'S DISEASE: PRELIMINARY REAL-LIFE RESULTS

Guillaume Bouguen  et al.

EFFECTIVENESS AND SAFETY OF TOFACITINIB IN PATIENTS WITH CHRONIC ANTI-TNF REFRACTORY ULCERATIVE PROCTITIS: A MULTICENTER COHORT STUDY FROM THE GETAID
EFFECTIVENESS AND SAFETY OF TOFACITINIB IN PATIENTS WITH CHRONIC ANTI-TNF REFRACTORY ULCERATIVE PROCTITIS: A MULTICENTER COHORT STUDY FROM THE GETAID

Guillaume Bouguen  et al.

IMPACT OF BIOLOGICS ON THE RISK OF EARLY POSTOPERATIVE COMPLICATIONS IN CROHN'S DISEASE: A FRENCH NATIONWIDE STUDY
IMPACT OF BIOLOGICS ON THE RISK OF EARLY POSTOPERATIVE COMPLICATIONS IN CROHN'S DISEASE: A FRENCH NATIONWIDE STUDY

Guillaume Bouguen  et al.

WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY
WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY

Guillaume Bouguen  et al.

REAL-WORLD MULTICENTER COMPARISON OF SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY BETWEEN TOFACITINIB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS AFTER FAILURE TO AT LEAST ONE ANTI-TNF AGENT
REAL-WORLD MULTICENTER COMPARISON OF SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY BETWEEN TOFACITINIB AND VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS AFTER FAILURE TO AT LEAST ONE ANTI-TNF AGENT

Guillaume Bouguen  et al.

IMPACT OF ABDOMINOPELVIC RADIOTHERAPY ON INFLAMMATORY BOWEL DISEASE ACTIVITY: A MULTICENTER COHORT STUDY FROM THE GETAID
IMPACT OF ABDOMINOPELVIC RADIOTHERAPY ON INFLAMMATORY BOWEL DISEASE ACTIVITY: A MULTICENTER COHORT STUDY FROM THE GETAID

Guillaume Bouguen  et al.

INFLIXIMAB PLUS AZATHIOPRINE AND QUICK STEROIDS DISCONTINUATION VERSUS AZATHIOPRINE PLUS STEROIDS IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS RESPONDING TO INTRAVENOUS STEROIDS: A PARALLEL, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL
INFLIXIMAB PLUS AZATHIOPRINE AND QUICK STEROIDS DISCONTINUATION VERSUS AZATHIOPRINE PLUS STEROIDS IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS RESPONDING TO INTRAVENOUS STEROIDS: A PARALLEL, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL

Guillaume Bouguen  et al.

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID
CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Guillaume Bouguen  et al.

Item 1 - 14 / 14
1